UPDATE: Cowen Starts Trillium Therapeutics (TRIL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Leerink Partners Starts Trillium Therapeutics (TRIL) at Outperform
April 27, 2015 6:21 AM EDTLeerink Partners initiates coverage on Trillium Therapeutics (NASDAQ: TRIL) with a Outperform rating and a price target of $29.00.
Analyst Michael Schmidt commented, "TRIL is an early stage Biotech company developing SIRPFC which blocks CD47, an emerging immuno-oncology (IO) target which is... More
